Á lódáil...
Improving clinical trial design for Duchenne muscular dystrophy
BACKGROUND: Currently, the most promising therapies for Duchenne muscular dystrophy (DMD) are exon skipping and stop codon read-through, two strategies aimed at restoring the expression of dystrophin. A phase 3 clinical trial with drisapersen, a drug designed to induce exon 51-skipping, has failed t...
Na minha lista:
| Foilsithe in: | BMC Neurol |
|---|---|
| Main Authors: | , |
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe: |
BioMed Central
2015
|
| Ábhair: | |
| Rochtain Ar Líne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4549867/ https://ncbi.nlm.nih.gov/pubmed/26306629 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12883-015-0408-z |
| Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|